La vendita allo scoperto per Crescent Energy dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Crescent Energy. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Crescent Energy (NYSE:CRGY) Azioni, Report sulle vendite allo scoperto

CRESCENT ENERGY INC-A

Crescent Energy

Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.

Crescent Energy Company Class A Common Stock

Crescent Energy Co

Barclays analyst Matthew Murphy maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Overweight and raises the price target from C$21.4 to C$21.6.

News

Price Target

Analyst Ratings

TSX:FM

Barclays Maintains Overweight on First Quantum Minerals, Raises Price Target to C$21.6

Animal health firm Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">consensus of $1.39</a>.
Adjusted net income for the first quarter of 2025 was $662 million, or $1.48 per diluted share. That&#8217;s an increase of 6% and 8%, respectively, <a href="https://www.benzinga.com/pressreleases/25/05/b45217035/zoetis-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">on an organic operational basis</a>.
Adjusted net income for the first quarter of 2025 excludes the net impact of $31 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt" rel="noreferrer noopener">Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal</a>
The company reported sales of $2.22 billion, up 1% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $2.19 billion</a>.
On an organic operational&nbsp;basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024.
Revenue in the U.S. segment was $1.2 billion, an increase of 2% compared with the first quarter of 2024 and an increase of 6% on an organic operational basis.
Sales of companion animal products increased by 8%, driven by Simparica Trio, the company&#8217;s flea tick and heartworm combination product, key dermatology products Apoquel&nbsp;and Cytopoint, and monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela&nbsp;for dogs and Solensia&nbsp;for cats.
Guidance: Zoetis raised its fiscal 2025 revenues guidance from $9.225 billion &#8211; $9.375 billion to  $9.425 billion &#8211; $9.575 billion, compared to the consensus of $9.33 billion.
The company maintains an organic operational growth of 6% to 8%. It expects a reported net income of $2.630 billion—$2.68 billion, compared to <a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">prior guidance of $2.57 billion &#8211; $2.62 billion</a>.
The animal company raised its adjusted net income guidance to $2.775 billion &#8211; $2.825 billion from $2.70 billion and $2.75 billion, with organic operational growth of 6% to 8% (compared to 5% &#8211; 7% earlier).
Zoetis forecasts a reported EPS of $5.85 to $5.95 compared to prior guidance of $5.70-$5.80 and adjusted EPS of $6.20-$6.30 from between $6.00 and $6.10, compared to a consensus of $6.09.
The company says the guidance reflects foreign exchange rates as of late April and the impact of enacted tariffs.
Price Action:&nbsp;ZTS stock is down 1.11% at $156.30 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45209967/biocryst-pharmaceuticals-soars-23-in-one-session-heres-why-it-surprised-investors" target="_blank" rel="noreferrer noopener">BioCryst Pharmaceuticals Soars 23% In One Session &#8211; Here&#8217;s Why It Surprised Investors</a></li>
</ul>

Earnings

Large Cap

Guidance

Health Care

General

Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact

WIIM

BIAF

BioAffinity Technologies shares are trading lower after the company announced the pricing of its $3.25 million offering.

Barclays analyst George Wang maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Equal-Weight and lowers the price target from $245 to $234.

Barclays Maintains Equal-Weight on Fabrinet, Lowers Price Target to $234

ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) reported a good first-quarter beat and raised its <a href="https://www.benzinga.com/quote/TDUP/guidance">full-year guidance</a>, driven by record new buyer growth, according to Telsey Advisory Group.
The ThredUp Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5888c53977f9dd0001877a22/dana-telsey">Analyst Dana Telsey</a> maintained an Outperform rating, while raising the price target from $6 to $7.
The ThredUp Thesis: The company reported better-than-expected results "across the board," with total revenue of $71.3 million and adjusted EBITDA of $3.8 million, topping consensus of $2.2 million and $68.2 million, respectively, Telsey said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
ThredUp posted a record 95% growth in new buyers in the first quarter, "while orders also grew mid-teens in the period," the analyst added.
Strong new buyer growth continued into the second quarter, with April recording the strongest customer acquisition month in the company&#8217;s history, Telsey stated.
Management raised their 2025 revenue guidance from $270-$280 million to $281-$291 million, ahead of consensus of $276.4 million, Telsey said. The new revenue guidance reflects "an improvement in the remainder of the year," she further wrote.
TDUP Price Action: Shares of ThredUp jumped 32% to $5.88 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://in.benzinga.com/content/44890152/j-b-hunt-transport-overcorrects-into-a-buying-opportunity"> Top 2 Consumer Stocks That May Implode In May</a>  </li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Long Ideas

Reiteration

Movers

Trading Ideas

TDUP

ThredUp Shares Jump 32% On Record Customer Growth, Upbeat Forecast; Analyst Sees More Upside

OTTR

Otter Tail shares are trading lower after the company reported worse-than-expected Q1 sales results and issued FY25 EPS guidance below estimates.

ARMK

Aramark shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) shares are trading higher premarket on Tuesday after the company reported first-quarter adjusted EPS of $1.76, up from $1.44 a year ago and beating the consensus of $1.60. 
Revenues of&nbsp;$8.25 billion&nbsp;exceeded the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of&nbsp;$8.06 billion</a>.
Electric Utilities and Infrastructure&#8217;s segment income increased to $1.28 billion from $1.02 billion a year ago, led by higher retail sales volumes, better weather and the implementation of new rates.
On the other hand, the Gas Utilities and Infrastructure segment reported segment income of&nbsp;$349&nbsp;million compared to&nbsp;$284&nbsp;million in the&nbsp;first quarter of 2024, aided by higher growth rates.
At the end of the quarter, operating cash flow was $2.2 billion, and cash and equivalents were $475 million. 
FY25&nbsp;Outlook&nbsp;Reaffirmed: Duke Energy expects adjusted EPS of&nbsp;$6.17&nbsp;–&nbsp;$6.42&nbsp;<a target="_blank" href="https://www.benzinga.com//node/40190824" rel="noreferrer noopener">vs consensus of&nbsp;$6.32</a>.
The company reaffirmed its long-term adjusted EPS growth rate of 5% to 7% through 2029, which is off the 2025 midpoint of $6.30.
Investors can gain exposure to the stock via&nbsp;SPDR Select Sector Fund – Utilities&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) and&nbsp;Vanguard Utilities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPU#NYSE">VPU</a>).
Price Action: DUK shares are up 0.83% at $121.75 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45078739" target="_blank" rel="noreferrer noopener">Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Photo: Shutterstock

Equities

Duke Energy's Segment Strength Fuels Q1 Beat, Reaffirms Guidance

MIND C.T.I. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDO#NASDAQ">MNDO</a>) reported quarterly earnings of $0.02 per share. This is a 71.43 percent decrease over earnings of $0.07 per share from the same period last year. The company reported $5.00 million in sales this quarter. This is a 13.27 percent decrease over sales of $5.76 million the same period last year.

MNDO

MIND C.T.I. Q1 EPS $0.02 Down From $0.07 YoY, Sales $5.00M Down From $5.76M YoY

- Court Filing Case: 24-2277

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

JAZZ

A U.S. Federal Appeals Court Has Partially Overturned A Lower Court's Injunction, Allowing Avadel Pharmaceuticals To Seek FDA Approval And Market Its Narcolepsy Drug, Lumryz, For Idiopathic Hypersomnia, While Upholding The Ban On Clinical Trials And Open-Label Extensions

AVNT

Avient shares are trading higher after the company issued FY25 adjusted EPS guidance with its midpoint above estimates.

Barclays analyst Adrienne Yih downgrades Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) from Overweight to Equal-Weight and raises the price target from $53 to $63.

Downgrades

Barclays Downgrades Skechers USA to Equal-Weight, Raises Price Target to $63

GBTG

Global Business Travel Group shares are trading lower after the company reported a Q1 revenue miss, issued Q2 sales guidance below estimates, and cut its FY25 sales guidance.

Fidelity National Information Services shares are trading lower. The comapny issued Q1 financial results.

Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) has outperformed the market over the past 10 years by 2.4% on an annualized basis producing an average annual return of 12.72%. Currently, Roper Technologies has a market capitalization of $61.33 billion. 
Buying $100 In ROP: If an investor had bought $100 of ROP stock 10 years ago, it would be worth $333.78 today based on a price of $571.13 for ROP at the time of writing.
<h3>Roper Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746542722_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Roper Technologies 10 Years Ago Would Be Worth Today

NOVT

Novanta shares are trading lower after the company issued soft Q2 guidance.

Bitcoin (BTC) is trading slightly lower on Tuesday, down 0.6% to $93,931, extending a slow decline that has seen the leading cryptocurrency fall 1% over the past week. Still, <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-btc-best-bonuses-august-2024#:~:text=Users%20need%20to%20set%20up,bank%20transfers%2C%20and%20other%20cryptocurrencies.">Bitcoin is up 14.14% over the past month</a>, buoyed by institutional inflows and persistent demand for safe-haven assets amid macro uncertainty.
Tuesday&#8217;s trading reflects a more cautious tone, though. As markets await Federal Reserve Chair Jerome Powell's post-FOMC comments on Wednesday, data from the options market suggests that traders are seeking downside protection—though not in a panic.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade on Coinbase</a>.</li>
</ul>
&#8220;We have only seen some nuanced demand for protective BTC puts, reflecting limited caution among sophisticated traders,&#8221; Luuk Strijers, CEO of crypto options exchange Deribit, told CoinDesk.
Strijers added that implied volatility is subdued. "Spot BTC has retraced to around $94K, and Deribit's DVOL, our implied volatility index, sits at 45—levels we last observed in June 2024.&#8221;
On decentralized platforms like Derive.XYZ, however, traders appear more risk-averse. Put options at $82K, $78K, and $76K are seeing interest. Dr. Sean Dawson, head of Research at Derive.XYZ, told CoinDesk that there is "evidence of downside protection," surroudning concerns over the Fed meeting.&nbsp;
The Fed is expected to keep rates steady at 4.25%-4.50%, but markets will watch for any forward guidance. A hotter-than-expected jobs report last week has dampened hopes of a June rate cut, with odds falling to 30%.&nbsp;
If Powell pushes back against easing or hints at prolonged hawkishness due to inflation or trade risks, risk assets like BTC could come under pressure.
Additional headwinds come from Capitol Hill. According to CoinDesk, Senate Democrats are expressing renewed hesitation over stablecoin legislation due to President Trump's growing personal involvement in crypto-linked ventures, including World Librety Financial (CRYPTO: WLFI) and other meme tokens.&nbsp;
The optics of a regulatory process potentially benefiting the president have made bipartisan consensus elusive.
Bitcoin ETFs saw three straight days of net inflows, suggesting that long-term institutional appetite remains intact. U.S. Treasury Secretary Scott Bessent's recent comment that American interest rates now reflect sovereign credit risk adds fuel to the argument that crypto is becoming a hedge against political dysfunction as much as monetary uncertainty.
More Opportunities:
<ul>
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitcoin Slips Below $94K As Traders Brace For Powell's Fed Comments

Shares of Genius Sports Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) dropped 13.4% to $9.54 on Tuesday after the company reported a slight first-quarter revenue miss, posting $143.99 million against analysts' estimates of $144.06 million.
Despite the revenue miss, the company <a href="https://www.benzinga.com/pressreleases/25/05/b45216981/genius-sports-increases-first-quarter-group-revenue-and-group-adj-ebitda-by-20-and-188-respectivel">beat EPS expectations</a>, reporting a loss of 3 cents per share, narrower than the 4 cents projected and an improvement from last year&#8217;s 11 cent loss. 
What To Know: Revenue rose 20% year-over-year, driven by a 44% jump in its core betting technology segment, though media-related revenue declined 27%. Adjusted EBITDA soared 188% to $19.8 million, with margins expanding to 13.7%. 
Genius <a href="https://www.benzinga.com/pressreleases/25/05/b45216981/genius-sports-increases-first-quarter-group-revenue-and-group-adj-ebitda-by-20-and-188-respectivel">reaffirmed</a> its 2025 revenue guidance of $620 million, signaling confidence in sustained growth, profitability, and cash flow. CEO Mark Locke emphasized continued momentum in technology and product innovation. 
The company also announced a $100 million share repurchase program. Recent initiatives include expanding fan engagement tools and securing exclusive NCAA data rights through 2032.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45220645/us-trade-deficit-soars-to-record-140b-as-imports-rocket-ahead-of-trumps-tariffs">US Trade Deficit Soars To Record $140B As Imports Rocket Ahead Of Trump&#8217;s Tariffs</a>
<h2 class="wp-block-heading">How To Buy GENI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Genius Sports&#8217; case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GENI has a 52-week high of $11.40 and a 52-week low of $5.03.

GENI

Genius Sports (GENI) Shares Slide After Q1 Sales Miss: What's Going On?

IQVIA Holdings Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) reported a first-quarter 2025 adjusted EPS of $2.70, up from $2.54, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.63</a>.
Provider of advanced analytics reported sales of $3.83 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45217013/iqvia-reports-first-quarter-2025-results" rel="noreferrer noopener">consensus of $3.77 billion</a>.
Revenue increased 2.3% on a reported basis and 3.0% at constant currency.
<ul>
<li>Technology &amp; Analytics Solutions (TAS) revenue of $1.55 billion grew 6.4% on a reported basis and 7.6% at constant currency.</li>
<li>Research &amp; Development Solutions (R&amp;DS) revenue of $2.10 billion increased 0.3% on a reported basis and 1.1% at constant currency. Excluding reimbursed expenses, R&amp;DS revenue grew 1.2% on a reported basis.</li>
<li>Contract Sales &amp; Medical Solutions (CSMS) revenue of $181 million, down 4.2% on a reported basis and 2.1% at constant currency.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43945075/dan-loeb-adjusts-healthcare-holdings-danaher-stake-trimmed-as-thermo-fisher-gains-favor" rel="noreferrer noopener">Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor</a>
As of March 31, 2025, R&amp;DS contracted backlog, including reimbursed expenses, was $31.5 billion, growing 4.8 percent year-over-year and 4.6 percent at constant currency. The company expects approximately $7.9 billion of this backlog to convert to revenue in the next twelve months. First quarter net new bookings were $2.1 billion, representing a book-to-bill ratio of 1.02x and resulting in a trailing twelve-month book-to-bill ratio of 1.14x.
&#8220;IQVIA delivered strong revenue and profit performance, at the high-end of our expectations,&#8221; said Ari Bousbib, chairman and CEO of IQVIA. &#8220;In the clinical trial business, we experienced delayed decision-making by customers on new programs, reflecting incremental macroeconomic and industry sector uncertainty. Despite the environment, our R&amp;DS forward-looking indicators such as qualified pipeline, RFP flow, and backlog continued to grow. On the commercial side, the TAS business delivered above target performance, with revenue growth of 7.6 percent at constant currency. Our strong financial results demonstrate that we are navigating the current market conditions more effectively than our sector, reflecting the scale and strength of our differentiated portfolio and the resilience of our operational execution.&#8221;
Guidance:&nbsp;IQVIA Holdings raises its 2025 outlook for sales from $15.725 billion—$16.125 billion to $16 billion—$16.40 billion versus a consensus of $16.03 billion.
The company affirms adjusted EPS of $11.70-$12.10 versus the consensus of $11.83 and adjusted EBITDA of $3.765 billion—$3.885 billion.
Price Action: IQV stock is down 1.87% at $149.46 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45221976/ferrari-beats-q1-holds-2025-outlook-but-warns-tariffs-could-squeeze-profit-margins" target="_blank" rel="noreferrer noopener">Ferrari Beats Q1, Holds 2025 Outlook But Warns Tariffs Could Squeeze Profit Margins</a></li>
</ul>
Photo: Shutterstock

IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions 'Effectively' Says CEO

CERT

Certara shares are trading lower following Q1 reported financial results.

Press Releases

Crescent Energy Company Announces Pricing of Upsized Public Offering of Class A Common Stock

Crescent Energy Announces Offering of $300 Million Private Placement of Additional 7.625% Senior Notes Due 2032

Crescent Energy Announces Pricing of Upsized $400 Million Private Placement of Additional 7.625% Senior Notes Due 2032

Crescent Energy Closes Accretive Central Eagle Ford Bolt-On

Crescent Energy Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Crescent Energy Reports Fourth Quarter and Full Year 2024 Results

Crescent Energy Announces Transition to Single Class of Common Stock and Elimination of Up-C Structure

Crescent Energy Schedules First Quarter 2025 Earnings Release and Conference Call

Crescent Energy Completes Accretive Sale of Non-Operated Permian Basin Assets

Crescent Energy Reports First Quarter 2025 Results

CRGY

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

Civitas Resources

CNX Resources

California Resources Corporation Common Stock

California Resources

Dorchester Minerals, L.P. - Common Units Representing Limited Partnership Interests

Dorchester Minerals

Gulfport Energy Corporation Common Shares

Gulfport Energy

Granite Ridge Resources, Inc. Common Stock

Granite Ridge Resources

HighPeak Energy

Kosmos Energy

Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Mach Natural Resources LP Common Units representing Limited Partner Interests

Mach Natural Resources

Matador Resources

Murphy Oil

Northern Oil & Gas

Riley Exploration Permian, Inc. Common Stock

Riley Exploration Permian

Sabine Royalty

SM Energy

Sable Offshore

Sitio Royalties Corp. Class A Common Stock

Sitio Royalties

Talos Energy

TXO Partners, L.P. Common Units Representing Limited Partner Interests

TXO Partners

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Comments

Crescent Energy

Vendite allo scoperto

Crescent Energy (NYSE:CRGY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO